Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc.

NRIXNYSE / NASDAQHealthcareSmall cap

$15.30+$0.46 (+3.1%)

Last close · Data as of Nov 6, 2026

Market cap
$1.6B
Revenue
$84.0M
Net margin
-314.9%
ROCE
-53.0%

+22.2% over the last year

Nurix Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools

Open technical chart
Open technical chartCandles, 9 moving averages, RSI, MACD, drawing tools

Performance

Price change over each period, before dividends.

1M
-32.3%
3M
-39.3%
6M
-9.4%
1Y
+22.2%
5Y
-55.1%

52-week range

Day change +$0.46 (+3.1%) from $15 to $15 · Last close Nov 6, 2026

Best weekday to invest, historically

The same weekly amount in NRIX, bought on each weekday since 2021.

News & filings

What Nurix Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

Strengths1

  • Revenue has grown at 29.5% CAGR over 3 years

Concerns1

  • Negative free cash flow

Rule-based from financial data. Not advice.

About the company

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.

Read moreShow less

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Sector
Healthcare
Shares outstanding
101.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.6B
P/B
2.9x
EV / Sales
12.4x
P/S
18.8x
52-week high
$27.79
52-week low
$12.17

Profitability

Operating margin
-340.2%
Net margin
-314.9%
EBITDA margin
-317.7%
ROE
-49.1%
ROCE
-53.0%
ROIC
-64.9%
ROA
-38.4%
Asset turnover
0.12

Growth

Revenue
$84.0M
Revenue growth, 1Y
54.0%
Revenue CAGR, 3Y
29.5%
Net profit growth, 1Y
36.6%
Free cash flow
-$263.5M

Solvency

Current ratio
7.02
Debt / Equity
0.10
Debt / Assets
0.08
CFO / Net profit
0.94
Cash / Market cap
37.5%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$84.0M
Gross profit$84.0M
Operating expenses$369.7M
Research and development$316.9M
Selling, general and administrative$52.7M
Operating income-$285.7M
Interest and other$22.0M
Pretax income-$263.7M
Tax and other$760.0k
Net income-$264.5M

Revenue and net profit

Revenue grew 54.0% in FY2025; net profit is the dashed line.

Nurix Therapeutics, Inc. revenue and net profit by fiscal year
Nurix Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$38.6M-$180.4M
FY2023$77.0M-$143.9M
FY2024$54.5M-$193.6M
FY2025$84.0M-$264.5M

Cash flows

FY2025: -$249.5M from operations, -$263.5M free after investment (dashed).

Nurix Therapeutics, Inc. operating and free cash flow by fiscal year
Nurix Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$159.8M-$172.1M
FY2023-$81.4M-$89.8M
FY2024-$172.6M-$181.9M
FY2025-$249.5M-$263.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$84.0M+54.0%1Y
EBITDA
-$266.8M
Net profit
-$264.5M
Cash from operations
-$249.5M
Free cash flow
-$263.5M
Revenue CAGR, 3Y
29.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$84.0M-$266.8M-$264.5M-$263.5M-49.1%+54.0%+36.6%

Monthly returns

Month-by-month returns of NRIX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$688.1M
Liabilities$149.4M
Equity$538.8M
Paid-in capital$1.5B
Retained earnings-$1.0B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; NRIX highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. Nurix Therapeutics, Inc. (this company)12.4x

Not shown (no positive earnings and no EV / Sales): Capricor Therapeutics, Inc., Tyra Biosciences, Inc., Amylyx Pharmaceuticals, Inc., ArriVent BioPharma, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Nurix Therapeutics, Inc.NRIXthis company$1.6B—2.9x-49.1%—
Capricor Therapeutics, Inc.CAPR$1.6B-15.4x5.3x-34.4%-13.4x
Tyra Biosciences, Inc.TYRA$1.6B-13.5x6.2x-46.3%-11.7x
Syndax Pharmaceuticals, Inc.SNDX$1.6B-5.6x24.7x-441.6%-7.2x
Amylyx Pharmaceuticals, Inc.AMLX$1.6B-11.0x5.2x-47.4%-9.0x
agilon health, inc.AGL$1.6B—12.5x-308.8%—
Sonida Senior Living, Inc.SNDA$1.6B-22.2x-142770.5x643445.5%96.8x
Vir Biotechnology, Inc.VIR$1.5B—2.0x-57.2%—
ArriVent BioPharma, Inc.AVBP$1.5B—5.0x-54.1%—
Peer median—-13.5x5.3x-50.8%-9.0x

Year-to-date ROI

NRIX since 1 January, against earlier years.

Historical volatility

NRIX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Nurix Therapeutics, Inc. operating margin by fiscal year
Nurix Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-476.0%
FY2023-201.4%
FY2024-390.5%
FY2025-340.2%
LineFY2025
Operating expensesOperating Expense$369.6M
Research and developmentResearch And Development$316.9M
Total expensesTotal Expenses$369.6M
Pretax incomePretax Income-$263.7M

Learn while you research

Academy chapters picked for Nurix Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing54% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →